West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Big Pharma spends millions of dollars on federal lobbying to protect its interests and prevent fair competition in the ...
Pharmaceutical companies are cautiously stepping ... fierce competition in the GLP-1 space, the rise of community-based trials, and a more grounded perspective on decentralised clinical trials ...
Discover key insights from West Pharmaceutical Services' Q4 2024 earnings call, highlighting growth in GLP-1 elastomers, biologics, and HVP components.
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted the ire of a pharmaceutical ... a prescription medicine. GLP-1 agonist semaglutide ...
Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...
As part of NJBIZ’s latest virtual discussion, business leaders in New Jersey weighed in on what to expect in the first 100 ...